Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912747 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL4042945 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912720 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912761 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912156 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912868 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912744 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912200 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912740 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB | |
| SCHEMBL5912098 | 0.98 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173205-A1 | Process for producing w-cyanoaldehyde compound | UBE INDUSTRIES, LTD. (JP) | 2006-08-03 | — | — | US | claimed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | BEAM THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025104695-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES THEREOF | Corti Therapeutics Pte. Ltd. (SG) | 2025-05-22 | — | — | WO | disclosed |
| US-12268753-B2 | Nanomaterials comprising a biodegradable feature | BEAM THERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4281080-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | Beam Therapeutics Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4262819-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20060173205-A1 | Process for producing w-cyanoaldehyde compound | UBE INDUSTRIES, LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4140717-A | Process for halogenating α,α-dialkoxyalkyl ketoximes | ALLIED CHEMICAL CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173205-A1 | Process for producing w-cyanoaldehyde compound | FASN, ALOX5, ALOX15B | ALDH1A1 692/4885KDM4E 2068/4885USP2 2036/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | ALDH1A1 619/4885KDM4E 1939/4885USP2 3993/4885 |
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | ALDH1A1 1371/4885KDM4E 686/4885USP2 2774/4885 |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | ALDH1A1 331/4885KDM4E 1523/4885USP2 1129/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | ALDH1A1 984/4885KDM4E 4299/4885USP2 4124/4885 |
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | LDLR, TGFBR2, MSR1 | ALDH1A1 1706/4885KDM4E 627/4885USP2 2604/4885 |
| US-12268753-B2 | Nanomaterials comprising a biodegradable feature | LIPA, CD63, LIPG | ALDH1A1 2294/4885KDM4E 3930/4885USP2 1009/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | ALDH1A1 2079/4885KDM4E 493/4885USP2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.